

09/724/613

09567863

FILE 'HOME' ENTERED AT 08:58:18 ON 07 APR 2004

=> file biosis medline caplus wpis uspatfull

'WPIS' IS NOT A VALID FILE NAME

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

ENTER A FILE NAME OR (IGNORE):wpids

COST IN U.S. DOLLARS

| SINCE FILE | TOTAL   |
|------------|---------|
| ENTRY      | SESSION |
| 0.21       | 0.21    |

FULL ESTIMATED COST

FILE 'BIOSIS' ENTERED AT 08:58:49 ON 07 APR 2004  
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'MEDLINE' ENTERED AT 08:58:49 ON 07 APR 2004

FILE 'CAPLUS' ENTERED AT 08:58:49 ON 07 APR 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 08:58:49 ON 07 APR 2004  
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'USPATFULL' ENTERED AT 08:58:49 ON 07 APR 2004  
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

\*\*\* YOU HAVE NEW

09567863

=> s macera? (4a) whole tissue and cationic surfactant and protease and buffer  
L2 1 MACERA? (4A) WHOLE TISSUE AND CATIONIC SURFACTANT AND PROTEASE  
AND BUFFER

=> d l2 bib abs

L2 ANSWER 1 OF 1 USPATFULL on STN  
AN 2002:314662 USPATFULL  
TI Compositions, methods, and kits for isolating nucleic acids using  
surfactants and proteases  
IN Greenfield, Lawrence, San Mateo, CA, UNITED STATES  
Montesclaros, Luz, Pittsburg, CA, UNITED STATES  
PI US 2002177139 A1 20021128  
AI US 2001-997169 A1 20011128 (9)  
RLI Continuation-in-part of Ser. No. US 2000-724613, filed on 28 Nov 2000,  
PENDING  
DT Utility  
FS APPLICATION  
LREP Finnegan, Henderson, Farabow,, Garrett & Dunner, L.L.P., 1300 I Street,  
N.W., Washington, DC, 20005-3315  
CLMN Number of Claims: 64  
ECL Exemplary Claim: 1  
DRWN 32 Drawing Page(s)  
LN.CNT 2457  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The invention relates to compositions and methods for isolating nucleic  
acids from biological samples, including whole tissue. The invention  
also provides kits for isolating nucleic acids from biological samples.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s whole tissue and cationic surfactant and protease and buffer  
L3 4 WHOLE TISSUE AND CATIONIC SURFACTANT AND PROTEASE AND BUFFER

=> s l3 not l2  
L4 3 L3 NOT L2

=> dup rem l4  
PROCESSING COMPLETED FOR L4  
L5 2 DUP REM L4 (1 DUPLICATE REMOVED)

=> d l5 bib abs 1-2

L5 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 1  
AN 2002:869079 CAPLUS  
DN 137:365972  
TI Isolation of nucleic acids from biological samples using surfactants and  
proteases  
IN Greenfield, I. Larry  
PA PE Corporation, USA; Applera Corporation  
SO PCT Int. Appl., 129 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 2

|    | PATENT NO.    | KIND | DATE     | APPLICATION NO. | DATE     |
|----|---------------|------|----------|-----------------|----------|
| PI | WO 2002090539 | A2   | 20021114 | WO 2001-US45071 | 20011128 |
|    | WO 2002090539 | A3   | 20030807 |                 |          |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,  
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,  
 UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,  
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,  
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1354036 A2 20031022 EP 2001-274041 20011128

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRAI US 2000-724613 A 20001128

WO 2001-US45071 W 20011128

AB The invention relates to compns. and methods for isolating nucleic acids from biol. samples, including **whole tissue**. The method comprises contacting the biol. sample with a disrupting **buffer** containing proteases (e.g., Proteinase K) and a **cationic surfactant** (e.g., CTAB). The **cationic surfactant** is then neutralized either by its removal or by use of a second nonionic surfactants (e.g., Tween 20). Nucleic acids are then isolated by binding to a solid phase, such as glass fiber GF/B filters. The effects of cationic surfactants on activity of proteinase K, and the solubility of surfactants in different chaotropes is investigated to identify optimal cationic surfactants and salts. The invention also provides kits for isolating nucleic acids from biol. samples.

L5 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:907069 CAPLUS

DN 138:1959

TI Compositions, methods, and kits for isolating nucleic acids using surfactants and proteases

IN Greenfield, Lawrence; Montesclaros, Luz

PA USA

SO U.S. Pat. Appl. Publ., 57 pp., Cont.-in-part of U.S. Ser. No. 724,613.  
 CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

|      | PATENT NO.     | KIND | DATE     | APPLICATION NO. | DATE     |
|------|----------------|------|----------|-----------------|----------|
| PI   | US 2002177139  | A1   | 20021128 | US 2001-997169  | 20011128 |
| PRAI | US 2000-724613 | A2   | 20001128 |                 |          |

AB The invention relates to compns. and methods for isolating nucleic acids from biol. samples, including **whole tissue**. The invention also provides kits for isolating nucleic acids from biol. samples. A method for obtaining nucleic acid from a biol. sample and binding the nucleic acid to a solid phase comprises (a) contacting the biol. sample with a disrupting **buffer**, wherein the disrupting **buffer** comprises a **protease** and a **cationic surfactant**; (b) substantially neutralizing the **cationic surfactant**; and (c) binding the nucleic acid to a solid phase. Genomic DNA was isolated from several rat tissues and mouse tail using a digestion solution containing 1 mg of Proteinase K, 1 % DTAB, 100 mM Tris-HCl

(pH

8.0), 20  $\mu$ M ATA, and 20 mM CaCl<sub>2</sub> and incubating for 60 min at 65°. Most of the tissues were effectively digested in less than one hour. Digestion of liver, brain and kidney were about 95 % complete after one hour. Following digestion, binding solution containing 5 M GuSCN, 50 mM MES (pH 6.0), 20 mM EDTA, and 6 % Tween 20 was then added to each sample and the samples were placed on GF/B filter membranes for washing and recovery of DNA.

09567863

=>

=> s tissue and cationic surfactant and protease and buffer  
L6 50 TISSUE AND CATIONIC SURFACTANT AND PROTEASE AND BUFFER

=> s l6 not l3

L7 46 L6 NOT L3

=> dup rem l7

PROCESSING COMPLETED FOR L7

L8 46 DUP REM L7 (0 DUPLICATES REMOVED)

=> s l8 and py=2000

L9 3 L8 AND PY=2000

=> d l9 bib abs 1-3

L9 ANSWER 1 OF 3 USPATFULL on STN

AN 2000:174129 USPATFULL

TI Preparation for the application of agents in mini-droplets

IN Cevc, Gregor, Heimstetten, Germany, Federal Republic of

PA Idea AG, Munich, Germany, Federal Republic of (non-U.S. corporation)

PI US 6165500 20001226 <--

AI US 1992-844664 19920408 (7)

PRAI DE 1990-4026834 19900824

DE 1990-4026833 19900824

DE 1991-4107153 19910306

WO 1991-EP1596 19910822

DT Utility

FS Granted

EXNAM Primary Examiner: Kishore, Gollamudi S.

LREP Davidson, Davidson & Kappel, LLC

CLMN Number of Claims: 35

ECL Exemplary Claim: 1

DRWN 31 Drawing Figure(s); 21 Drawing Page(s)

LN.CNT 4336

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a preparation for the application of agents in the form of minuscule droplets of fluid, in particular provided with membrane-like structures consisting of one or several layers of amphiphilic molecules, or an amphiphilic carrier substance, in particular for transporting the agent into and through natural barriers such as skin and similar materials. The preparation contains a concentration of edge active substances which amounts to up to 99 mol-% of the agent concentration which is required for the induction of droplet solubilization. Such preparations are suitable, for example, for the non-invasive applications of antidiabetics, in particular of insulin. The invention, moreover, relates to the methods for the preparation of such formulations.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 2 OF 3 USPATFULL on STN

AN 2000:137855 USPATFULL

TI Drug delivery via therapeutic hydrogels

IN DiCosmo, Frank, Richmond Hill, Canada

DiTizio, Valerio, North York, Canada

PA Uroteq Inc., Ontario, Canada (non-U.S. corporation)

PI US 6132765 20001017 <--

AI US 1997-843342 19970415 (8)

RLI Continuation-in-part of Ser. No. US 1996-631326, filed on 12 Apr 1996, now abandoned

09567863

DT Utility  
FS Granted  
EXNAM Primary Examiner: Kishore, Gollamudi S.  
LREP Burns, Doane, Swecker & Mathis, L.L.P.  
CLMN Number of Claims: 18  
ECL Exemplary Claim: 1  
DRWN 5 Drawing Figure(s); 5 Drawing Page(s)  
LN.CNT 1097

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to a vehicle for effecting drug delivery from a solid substrate. Hydrogels loaded with liposomal therapeutic agents such as antibiotics are covalently bonded to the surface of substrates such as in-dwelling medical devices, such as implants, catheters, and the like. The present invention is particularly useful in the treatment and prevention of biofilm mediated infection often associated with the use of in-dwelling medical devices.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 3 OF 3 USPATFULL on STN  
AN 2000:87749 USPATFULL  
TI Oral peptide pharmaceutical products  
IN Stern, William, Tenafly, NJ, United States  
Gilligan, James P., Union, NJ, United States  
PA Unigene Laboratories, Inc., Fairfield, NJ, United States (U.S. corporation)  
PI US 6086918 20000711 <--  
WO 9733531 19970918  
AI US 1998-125500 19980819 (9)  
WO 1997-US4024 19970314  
19980819 PCT 371 date  
19980819 PCT 102(e) date  
RLI Continuation-in-part of Ser. No. US 1996-616250, filed on 15 Mar 1996, now patented, Pat. No. US 5912014  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Salimi, Ali  
LREP Ostrolenk, Faber, Gerb & Soffen, LLP  
CLMN Number of Claims: 55  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1353

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Bioavailability of peptide active agents to be administered orally is enhanced by a pharmaceutical composition providing targeted release of the peptide to the intestine by virtue of an acid-resistant protective vehicle which transports components of the invention through the stomach. The composition includes an absorption enhancer and a sufficient amount of a pH-lowering agent to lower local intestinal pH. All components are released together into the intestine with the peptide.

CAS INDEXING IS AVAILABLE

09567863

=> d 18 bib abs 1-46

L8 ANSWER 1 OF 46 USPATFULL on STN  
AN 2004:31254 USPATFULL  
TI Micellar systems  
IN Monahan, Sean D., Madison, WI, UNITED STATES  
Wolff, Jon A., Madison, WI, UNITED STATES  
Slattum, Paul M., Madison, WI, UNITED STATES  
Hagstrom, James E., Middleton, WI, UNITED STATES  
Budker, Vladimir G., Middleton, WI, UNITED STATES  
PI US 2004023393 A1 20040205  
AI US 2003-627247 A1 20030725 (10)  
RLI Division of Ser. No. US 2002-81461, filed on 21 Feb 2002, PENDING  
Continuation-in-part of Ser. No. US 1999-354957, filed on 16 Jul 1999,  
GRANTED, Pat. No. US 6429200  
DT Utility  
FS APPLICATION  
LREP Mark K. Johnson, Mirus Corporation, 505 S. Rosa Rd., Madison, WI, 53719  
CLMN Number of Claims: 26  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1791  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB A complex is described that is deliverable to a cell comprising  
inserting a nucleic acid or other cargo into a reverse micelle. The  
reverse micelle has the property to compact the nucleic acid for easier  
delivery

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 2 OF 46 USPATFULL on STN  
AN 2003:307044 USPATFULL  
TI Agents and method for increaseng brain chaperonin levels  
IN Holtzman, Jordan Loyal, Minneapolis, MN, UNITED STATES  
PI US 2003216480 A1 20031120  
AI US 2003-296730 A1 20030509 (10)  
WO 2001-US16914 20010523  
PRAI US 2000-60206854 20000524  
DT Utility  
FS APPLICATION  
LREP MERCHANT & GOULD PC, P.O. BOX 2903, MINNEAPOLIS, MN, 55402-0903  
CLMN Number of Claims: 45  
ECL Exemplary Claim: 1  
DRWN 1 Drawing Page(s)  
LN.CNT 1112  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The invention includes; a method of modulating a level of chaperone  
protein, a method of modulating a level of ERP57, a method with  
decreased levels of chaperone proteins, and a method of alleviating a  
symptom of Alzheimer's disease. The methods include administering to a  
patient a substituted biphenylmethane compound. Preferably the compound  
is an analog to methoxychlor. More preferably the compound is  
methoxychlor. The invention also includes pharmaceutical compositions.  
The pharmaceutical compositions include substituted biphenylmethanes and  
a pharmaceutically acceptable carrier. Preferably the pharmaceutical  
compositions include methoxychlor analogs and a pharmaceutically  
acceptable carrier. More preferably the pharmaceutical compositions  
include methoxychlor and a pharmaceutically acceptable carrier.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

09567863

L8 ANSWER 3 OF 46 USPATFULL on STN  
AN 2003:251066 USPATFULL  
TI Enhancement of in situ hybridization  
IN Kalra, Krishan L, Danville, CA, UNITED STATES  
Wang, Qian-Shu, San Ramon, CA, UNITED STATES  
Jin, Jia Kuan, San Francisco, CA, UNITED STATES  
PI US 2003175852 A1 20030918  
AI US 2003-381159 A1 20030317 (10)  
WO 2001-US29598 20010917  
PRAI US 2000-60232671 20000915  
DT Utility  
FS APPLICATION  
LREP The Law Offices Of James C Weseman, Suite 1600, 401 West A Street, San  
Diego, CA, 92101  
CLMN Number of Claims: 24  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1215  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Methods and compositions for improving in situ hybridization analysis of  
aldehyde fixed **tissue** are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 4 OF 46 USPATFULL on STN  
AN 2003:237277 USPATFULL  
TI Delivery of polynucleotide agents to the central nervous system  
IN Reinhard, Christoph, Alameda, CA, UNITED STATES  
Frey, William H., II, White Bear Lake, MN, UNITED STATES  
PA Chiron Corporation (U.S. corporation)  
PI US 2003165434 A1 20030904  
AI US 2002-126060 A1 20020419 (10)  
PRAI US 2001-285319P 20010420 (60)  
US 2001-288716P 20010504 (60)  
DT Utility  
FS APPLICATION  
LREP Chiron Corporation, Intellectual Property, P.O. Box 8097, Emeryville,  
CA, 94662-8097  
CLMN Number of Claims: 23  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 2860  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The present invention provides a method for delivering polynucleotide  
agents, particularly oligonucleotides, to the CNS of a mammal by way of  
a neural pathway originating in the nasal cavity or through a neural  
pathway originating in an extranasal **tissue** that is innervated  
by the trigeminal nerve.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 5 OF 46 USPATFULL on STN  
AN 2003:172766 USPATFULL  
TI Oral delivery of peptides using enzyme-cleavable membrane translocators  
IN Stern, William, Tenaflly, NJ, UNITED STATES  
Mehta, Nozer M., Randolph, NJ, UNITED STATES  
Ray, Martha V. L., Nutley, NJ, UNITED STATES  
PA Unigene Laboratories Inc. (U.S. corporation)  
PI US 2003118610 A1 20030626  
US 6673574 B2 20040106  
AI US 2001-997465 A1 20011129 (9)  
PRAI US 2000-250055P 20001130 (60)

09567863

DT Utility  
FS APPLICATION  
LREP OSTROLENK FABER GERB & SOFFEN, 1180 AVENUE OF THE AMERICAS, NEW YORK,  
NY, 100368403  
CLMN Number of Claims: 57  
ECL Exemplary Claim: 1  
DRWN 8 Drawing Page(s)  
LN.CNT 1507  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Bioavailability of peptide active agents to be administered orally is enhanced by a pharmaceutical composition providing targeted release of the peptide to the intestine in addition to having the active peptide linked to a membrane translocator which is capable of being at least partially cleaved in vivo by an enzyme. The composition includes an acid-resistant protective vehicle which transports components of the invention through the stomach and a sufficient amount of a pH-lowering agent to lower local intestinal pH. All components are released together into the intestine with the peptide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 6 OF 46 USPATFULL on STN  
AN 2003:152416 USPATFULL  
TI Antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases  
IN Squires, Meryl J., Barrington Hills, IL, UNITED STATES  
PI US 2003104082 A1 20030605  
AI US 2002-84759 A1 20020226 (10)  
RLI Continuation of Ser. No. US 1997-824041, filed on 26 Mar 1997, GRANTED, Pat. No. US 6350784 Continuation-in-part of Ser. No. US 1996-646988, filed on 8 May 1996, GRANTED, Pat. No. US 6355684 Continuation-in-part of Ser. No. US 1996-600217, filed on 12 Feb 1996, GRANTED, Pat. No. US 6348503  
DT Utility  
FS APPLICATION  
LREP Welsh & Katz, Ltd., Thomas W. Tolpin, 22nd Floor, 120 South Riverside Plaza, Chicago, IL, 60606  
CLMN Number of Claims: 34  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 3087

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An improved medical treatment and medicine is provided to quickly and safely resolve HIV and other microbial infections. The inexpensive medicine can be self administered and maintained for the prescribed time. The attractive medicine comprises an antimicrobial concentrate comprising microbe inhibitors, phytochemicals or isolates. Desirably, the effective medicine comprises a surfactant and an aqueous carrier or solvent and a nutrient. In the preferred form, the medicine comprises: Echinacea and Commiphora myrrha phytochemicals, benzalkonium chloride, a sterile water solution, and folic acid.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 7 OF 46 USPATFULL on STN  
AN 2003:152407 USPATFULL  
TI Methods for enhancing fluid flow through an obstructed vascular site, and systems and kits for use in practicing the same  
IN Johansson, Peter, Campbell, CA, UNITED STATES  
Delaney, David, Los Gatos, CA, UNITED STATES  
Constantz, Brent, Menlo Park, CA, UNITED STATES  
PI US 2003104073 A1 20030605



09567863

AI US 2002-265174 A1 20021004 (10)  
RLI Division of Ser. No. US 2001-774469, filed on 30 Jan 2001, GRANTED, Pat. No. US 6533767 Continuation-in-part of Ser. No. US 2000-528576, filed on 20 Mar 2000, GRANTED, Pat. No. US 6488671  
DT Utility  
FS APPLICATION  
LREP BOZICEVIC, FIELD & FRANCIS LLP, 200 MIDDLEFIELD RD, SUITE 200, MENLO PARK, CA, 94025  
CLMN Number of Claims: 51  
ECL Exemplary Claim: 1  
DRWN 7 Drawing Page(s)  
LN.CNT 2217  
AB Methods of enhancing fluid flow through a vascular site occupied by a vascular occlusion, as well as systems and kits for use in practicing the same, are provided. In practicing the subject methods, the vascular site is flushed simultaneously with a first dissolution fluid (e.g., an organic matter dissolution fluid and/or an inorganic matter dissolution fluid), and a second dissolution fluid attenuating fluid, where flushing is carried out in a manner such that only a surface of the vascular occlusion is contacted with the non-attenuated dissolution fluid. Examples of dissolution fluid/dissolution fluid attenuating fluid pairs include: (1) oxidizing agent fluid and fluid comprising oxidizable neutralizing agent; (2) surfactant fluid and phosphate buffered saline; (3) acidic solution and phosphate buffered saline; etc. Flushing is carried out in this manner for a period of time sufficient for fluid flow through the vascular site to be enhanced, e.g. increased or established. The subject methods, systems and kits for practicing the same find use in the treatment of a variety of different vascular diseases characterized by the presence of vascular occlusions, including both partial and total occlusions.

L8 ANSWER 8 OF 46 USPATFULL on STN  
AN 2003:105882 USPATFULL  
TI Method for administering agents to the central nervous system  
IN Frey, William H., II, White Bear Lake, MN, UNITED STATES  
Thorne, Robert Gary, Minneapolis, MN, UNITED STATES  
PA Chiron Corporation, Emeryville, CA (U.S. corporation)  
PI US 2003072793 A1 20030417  
AI US 2002-301185 A1 20021121 (10)  
RLI Continuation of Ser. No. US 1999-458562, filed on 9 Dec 1999, ABANDONED  
Continuation-in-part of Ser. No. US 1998-208539, filed on 9 Dec 1998, ABANDONED  
DT Utility  
FS APPLICATION  
LREP Chiron Corporation, 4560 Horton Street, Emeryville, CA, 94608-2916  
CLMN Number of Claims: 44  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 2245  
AB The present invention is directed to a method for delivering agents to the central nervous system by way of a **tissue** innervated by the trigeminal nerve that is outside the nasal cavity. Such a method of delivery can be useful in the treatment of central nervous system and/or brain disorders.

L8 ANSWER 9 OF 46 USPATFULL on STN  
AN 2003:78512 USPATFULL  
TI Methods and reagents for detecting endotoxin  
IN Chen, Lin, Frederick, MD, UNITED STATES  
Pepe, Michael, Frederick, MD, UNITED STATES

09567863

PA BioWhittaker, Inc., Walkersville, MD, UNITED STATES, 21793 (U.S. corporation)  
PI US 2003054432 A1 20030320  
AI US 2002-183992 A1 20020628 (10)  
PRAI US 2001-301125P 20010628 (60)  
DT Utility  
FS APPLICATION  
LREP BANNER & WITCOFF, 1001 G STREET N W, SUITE 1100, WASHINGTON, DC, 20001  
CLMN Number of Claims: 29  
ECL Exemplary Claim: 1  
DRWN 11 Drawing Page(s)  
LN.CNT 1732  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB A reagent containing a purified horseshoe crab Factor C, particularly a recombinantly produced Factor C, and a surfactant can be used in a sensitive, rapid, and reproducible assay to detect endotoxin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 10 OF 46 USPATFULL on STN  
AN 2003:50890 USPATFULL  
TI Water having a superior ability to disperse oil and fats  
IN Hattori, Toshimitsu, Fukuoka, JAPAN  
Matsushita, Kazuhiro, Tokyo, JAPAN  
PI US 2003035846 A1 20030220  
AI US 2002-118987 A1 20020409 (10)  
RLI Continuation-in-part of Ser. No. US 2000-589727, filed on 8 Jun 2000, PENDING  
DT Utility  
FS APPLICATION  
LREP Thomas W. Adams, Renner, Otto, Boisselle, & Sklar, L.L.P., 19th Floor, 1621 Euclid Avenue, Cleveland, OH, 44115  
CLMN Number of Claims: 3  
ECL Exemplary Claim: 1  
DRWN 2 Drawing Page(s)  
LN.CNT 1296  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Fine-clustered water made from pure water is obtained by fine clustering treatment of pure water and is able to disperse at least about 1.5 times as much glyceryl trioleate as purified water can disperse.

The water of the present invention can be used in pharmaceutical compositions, food compositions, cosmetic compositions, eye drop compositions, eye wash compositions, contact lens cleaner, agricultural chemical compositions, photo developing solution, and concrete compositions.

Especially, when the fine-clustered water of the present invention is used in pharmaceutical compositions, not only are the drugs dissolved easily in the water, but they are also rapidly absorbed via and delivered to **tissue** (oral mucosa, skin, mesentery) as compared with the purified water.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 11 OF 46 USPATFULL on STN  
AN 2003:37694 USPATFULL  
TI Micellar systems  
IN Monahan, Sean D., Madison, WI, UNITED STATES  
Wolff, Jon A., Madison, WI, UNITED STATES  
Slattum, Paul M., Madison, WI, UNITED STATES  
Hagstrom, James E., Middleton, WI, UNITED STATES

09567863

Budker, Vladimir G., Middleton, WI, UNITED STATES  
PI US 2003027339 A1 20030206  
US 6673612 B2 20040106  
AI US 2002-81461 A1 20020221 (10)  
RLI Continuation-in-part of Ser. No. US 1999-354957, filed on 16 Jul 1999,  
PENDING  
DT Utility  
FS APPLICATION  
LREP Mark K. Johnson, PO Box 510644, New Berlin, WI, 53151-0644  
CLMN Number of Claims: 26  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1789  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB A complex is described that is deliverable to a cell comprising  
inserting a nucleic acid or other cargo into a reverse micelle. The  
reverse micelle has the property to compact the nucleic acid for easier  
delivery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 12 OF 46 USPATFULL on STN  
AN 2003:337233 USPATFULL  
TI Mutant genes in Familial British Dementia and Familial Danish Dementia  
IN Ghiso, Jorge, Elmhurst, NY, United States  
Vidal, Ruben, Great Neck, NY, United States  
Frangione, Blas, New York, NY, United States  
PA New York University, New York, NY, United States (U.S. corporation)  
PI US 6670195 B1 20031230  
AI US 2000-579012 20000526 (9)  
PRAI US 1999-136238P 19990526 (60)  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Falk, Anne-Marie  
LREP Venable LLP, Livnat, Shmuel  
CLMN Number of Claims: 3  
ECL Exemplary Claim: 1  
DRWN 7 Drawing Figure(s); 5 Drawing Page(s)  
LN.CNT 2973  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Two novel mutant amyloid protein precursors (ABriPP and ADanPP) and  
their amyloid peptides (ABri and ADan) associated with Familial British  
Dementia and Familial Danish Dementia, respectively, are disclosed.  
Genetic constructs comprising DNA encoding these proteins is used to  
produced transgenic mammals that are useful models for neurological  
diseases associated with amyloid deposits, neurofibrillary tangles,  
non-neuritic plaques, neuronal degeneration and behavioral deficits  
characteristic of dementia and other symptoms of the human diseases.  
These models are used for testing potential therapeutic agents and  
methods. Also provided is a DNA-based test for detecting the mutations,  
the mutant proteins and peptides, antibodies specific for the proteins  
and peptides. Immunoassays permit detection of the mutant proteins,  
particularly in affected brain **tissue**, or detection of an  
antibody specific for a mutant peptide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 13 OF 46 USPATFULL on STN  
AN 2003:314482 USPATFULL  
TI Composition for transdermal and dermal administration of  
interferon- $\alpha$   
IN Foldvari, Marianna, Saskatoon, CANADA

09567863

Attah-Poku, Sam, Saskatchewan, CANADA  
PA PharmaDerm Laboratories, Ltd., CANADA (non-U.S. corporation)  
PI US 6656499 B1 20031202  
AI US 2000-709691 20001110 (9)  
PRAI US 1999-165107P 19991112 (60)  
US 2000-195549P 20000407 (60)  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Dees, Jose' G.; Assistant Examiner: DeWitty, Robert M  
LREP Mohr, Judy M., Perkins Coie LLP  
CLMN Number of Claims: 46  
ECL Exemplary Claim: 1  
DRWN 14 Drawing Figure(s); 5 Drawing Page(s)  
LN.CNT 1407

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A composition for transdermal and dermal administration of interferon- $\alpha$  is described. The composition is comprised of lipid vesicles including a fatty acylated amino acid and an oil-in-water emulsion. Interferon- $\alpha$  is entrapped in the vesicles.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 14 OF 46 USPATFULL on STN  
AN 2003:108859 USPATFULL  
TI Method for sequestration of skin irritants with substrate compositions  
IN Minerath, III, Bernard Joseph, Oshkosh, WI, United States  
Otts, David Roland, Appleton, WI, United States  
Huard, Linda Susan, Appleton, WI, United States  
Tyrrell, David John, Appleton, WI, United States  
DiLuccio, Robert Cosmo, Alpharetta, GA, United States  
Akin, Frank Jerrel, Marietta, GA, United States  
Buhrow, Chantel Spring, Weyauwega, WI, United States  
Everhart, Dennis Stein, Alpharetta, GA, United States  
Nelson, Brenda Marie, Appleton, WI, United States  
Shanklin, Gary Lee, Appleton, WI, United States  
PA Kimberly-Clark Worldwide, Inc., Neenah, WI, United States (U.S. corporation)

PI US 6551607 B1 20030422  
AI US 1999-474490 19991229 (9)  
PRAI US 1998-114497P 19981231 (60)  
US 1998-114496P 19981231 (60)  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Page, Thurman K.; Assistant Examiner: Ghali, Isis  
LREP Pauley Petersen Kinne & Erickson  
CLMN Number of Claims: 57  
ECL Exemplary Claim: 1  
DRWN 22 Drawing Figure(s); 13 Drawing Page(s)  
LN.CNT 2303

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a method of sequestering skin irritants with a skin irritant sequestering composition comprising a substrate, a hydrophilic skin irritant sequestering agent and a hydrophobic skin irritant sequestering agent. In one embodiment the sequestering agents are comprised of modified and non-modified clays. The present invention further also provides a method of sequestering skin irritants comprising administering to the stratum corneum of an individual's skin a skin irritant sequestering composition comprising a substrate, a skin irritant sequestering amount of a combination of hydrophilic and hydrophobic skin irritant sequestering agents. In one embodiment the skin irritants are bound to sequestering agents present on a substrate. In another embodiment the skin irritants are bound to sequestering

09567863

agents present on the skin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 15 OF 46 USPATFULL on STN  
AN 2003:47522 USPATFULL  
TI Substrate composition for sequestration of skin irritants  
IN Minerath, III, Bernard Joseph, Oshkosh, WI, United States  
Otts, David Roland, Appleton, WI, United States  
Huard, Linda Susan, Appleton, WI, United States  
Tyrrell, David John, Appleton, WI, United States  
DiLuccio, Robert Cosmo, Alpharetta, GA, United States  
Akin, Frank Jerrel, Marietta, GA, United States  
Buhrow, Chantel Spring, Weyauwega, WI, United States  
Everhart, Dennis Stein, Alpharetta, GA, United States  
Nelson, Brenda Marie, Appleton, WI, United States  
Shanklin, Gary Lee, Appleton, WI, United States  
PA Kimberly-Clark Worldwide, Inc., Neenah, WI, United States (U.S.  
corporation)  
PI US 6521241 B1 20030218  
AI US 1999-474307 19991229 (9)  
PRAI US 1998-114497P 19981231 (60)  
US 1998-114496P 19981231 (60)  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Page, Thurman K.; Assistant Examiner: Ghali, Isis  
LREP Pauley Petersen Kinne & Erickson  
CLMN Number of Claims: 49  
ECL Exemplary Claim: 1  
DRWN 22 Drawing Figure(s); 13 Drawing Page(s)  
LN.CNT 2280

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a skin irritant sequestering composition comprising a **tissue** substrate, a hydrophilic skin irritant sequestering agent and a hydrophobic skin irritant sequestering agent. In one embodiment the sequestering agents are comprised of modified and non-modified clays. In one embodiment, the skin irritants are bound to sequestering agents present on a substrate. In another embodiment the skin irritants are bound to sequestering agents present on the skin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 16 OF 46 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN  
AN 2003-370730 [35] WPIDS  
DNC C2003-098150  
TI Obtaining nucleic acid from biological sample and binding it to solid phase, by contacting sample with disrupting **buffer** comprising **protease** and **cationic surfactant**, and binding nucleic acid to solid phase.  
DC B04 D16  
IN GREENFIELD, L; MONTESCLAROS, L  
PA (GREE-I) GREENFIELD L; (MONT-I) MONTESCLAROS L  
CYC 1  
PI US 2002177139 A1 20021128 (200335)\* 57p  
ADT US 2002177139 A1 CIP of US 2000-724613 20001128, US 2001-997169 20011128  
PRAI US 2001-997169 20011128; US 2000-724613 20001128  
AN 2003-370730 [35] WPIDS  
AB US2002177139 A UPAB: 20030603  
NOVELTY - Obtaining (M) nucleic acid from a biological sample and binding the nucleic acid to a solid phase, comprising contacting the biological sample with a disrupting **buffer** (I) containing a

**protease** and **cationic surfactant** (II), optionally substantially neutralizing the **cationic surfactant**, and binding the nucleic acid to a solid phase, is new.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a kit comprising a **protease**, a **cationic surfactant**, and a second surfactant which neutralizes the **cationic surfactant**, or a **protease**, a **cationic surfactant**, a non-ionic surfactant which permits the binding of a nucleic acid to a solid phase in the presence of the **protease** and **cationic surfactant**, and a **buffer** with a high salt concentration.

USE - The method and the kit are useful for isolating and releasing nucleic acids from biological samples, and binding the isolated nucleic acid to a solid phase.

ADVANTAGE - The method and the kit reduce the time needed for sample preparation, decrease potential safety risks posed by multistep procedures that require repeated sample manipulation, and/or provide high integrity (i.e. minimally degraded) high molecular weight nucleic acid. The method and the kit also obviate the need for additional equipment to physically or mechanically disrupt **tissue**.

Dwg.0/30

L8 ANSWER 17 OF 46 USPTAFULL on STN  
 AN 2002:277843 USPTAFULL  
 TI Multi-dimensional proteomic analysis method  
 IN Akins, Robert E., JR., Newark, DE, UNITED STATES  
 PI US 2002153252 A1 20021024  
 AI US 2002-107812 A1 20020328 (10)  
 PRAI US 2001-279125P 20010328 (60)  
 DT Utility  
 FS APPLICATION  
 LREP McGuireWoods LLP, Suite 1800, 1750 Tysons Boulevard, McLean, VA, 22102  
 CLMN Number of Claims: 10  
 ECL Exemplary Claim: 1  
 DRWN 1 Drawing Page(s)  
 LN.CNT 521

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A multi-dimensional proteomic analysis method utilizing cationic electrophoresis is described. The method includes separating proteins in one direction using cationic electrophoresis and separating the proteins in a second orthogonal direction using other electrophoresis separation methods such as denaturing electrophoresis and electrophoresis subsequent to proteolytic cleavage or isofocussing. The two dimensional array may be used to determine various protein-protein interactions in a sample.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 18 OF 46 USPTAFULL on STN  
 AN 2002:273393 USPTAFULL  
 TI Universal antiviral composition  
 IN Burke, Peter A., Skillman, NJ, UNITED STATES  
 Coulter, Stephen L., Yardley, PA, UNITED STATES  
 PI US 2002151521 A1 20021017  
 AI US 2001-903289 A1 20010711 (9)  
 RLI Continuation-in-part of Ser. No. US 1999-281391, filed on 30 Mar 1999,  
 UNKNOWN  
 DT Utility  
 FS APPLICATION  
 LREP JOHN LEZDEY, SUITE A, 1409 NORTH FT HARRISON, CLEARWATER, FL, 33755  
 CLMN Number of Claims: 18  
 ECL Exemplary Claim: 1

09567863

DRWN No Drawings

LN.CNT 585

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There is provided an universal antiviral composition in the form of a lotion, foam or gel that is non-irritating. The composition contains an effective amount antimicrobicidal agent, an acidic **buffer** and wound healing agent so that the pH is an 7. The composition of the invention can be used in connection with packaged

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 19 OF 46 USPATFULL on STN

AN 2002:258404 USPATFULL

TI Method for administering a cytokine to the central nervous system and the lymphatic system

IN Frey, William H., II, North Oaks, MN, UNITED STATES

PA Chiron Corporation (U.S. corporation)

PI US 2002141971 A1 20021003

AI US 2002-102163 A1 20020320 (10)

RLI Continuation of Ser. No. US 2000-733168, filed on 8 Dec 2000, PENDING

PRAI US 1999-200708P 19991209 (60)

DT Utility

FS APPLICATION

LREP Corporate Patent Counsel, Intellectual Property, CHIRON CORPORATION, P.O. Box 8097, Emeryville, CA, 94662-8097

CLMN Number of Claims: 48

ECL Exemplary Claim: 1

DRWN 1 Drawing Page(s)

LN.CNT 2947

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to a method for delivering cytokines to the central nervous system and the lymphatic system by way of a **tissue** innervated by the trigeminal nerve and/or olfactory nerve. Cytokines include tumor necrosis factors, interleukins, interferons, particularly interferon- $\beta$  and its muteins such as IFN- $\beta$ .sub.ser17. Such a method of delivery can be useful in the treatment of central nervous system disorders, brain disorders, proliferative, viral, and/or autoimmune disorders such as Sjogren's disorder.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 20 OF 46 USPATFULL on STN

AN 2002:250831 USPATFULL

TI Nanogel networks including polyion polymer fragments and biological agent compositions thereof

IN Kabanov, Alexander V., Omaha, NE, UNITED STATES

Vinogradov, Sergey V., Omaha, NE, UNITED STATES

PI US 2002136769 A1 20020926

US 6696089 B2 20040224

AI US 2001-29682 A1 20011221 (10)

RLI Continuation-in-part of Ser. No. US 1998-146651, filed on 3 Sep 1998, GRANTED, Pat. No. US 6333051

DT Utility

FS APPLICATION

LREP Mathews, Collins, Shepherd & Gould, P.A., Suite 306, 100 Thanet Circle, Princeton, NJ, 08540

CLMN Number of Claims: 23

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1822

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

09567863

AB The present invention relates to nanogel networks having at least one cross-linked polyionic polymer fragment and at least one nonionic water-soluble polymer fragment, and compositions thereof, having at least one suitable biological agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 21 OF 46 USPATFULL on STN  
AN 2002:157611 USPATFULL  
TI Method for treating ischemic events affecting the central nervous system  
IN Frey, William H., II, White Bear Lake, MN, UNITED STATES  
PA Chiron Corporation (U.S. corporation)  
PI US 2002082215 A1 20020627  
AI US 2001-976620 A1 20011012 (9)  
PRAI US 2000-240549P 20001014 (60)  
DT Utility  
FS APPLICATION  
LREP Chiron Corporation, Intellectual Property Department, P.O. Box 8097, Emeryville, CA, 94662-8097  
CLMN Number of Claims: 26  
ECL Exemplary Claim: 1  
DRWN 10 Drawing Page(s)  
LN.CNT 1675

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed methods for reducing or preventing ischemic damage in the central nervous system of a mammal. The methods comprise administering to the nasal cavity of the mammal a pharmaceutical composition comprising a therapeutically effective amount of IGF-I or biologically active variant thereof. The IGF-I or variant thereof is absorbed through the nasal cavity and transported into the central nervous system of the mammal in an amount effective to reduce or prevent ischemic damage associated with an ischemic event. The methods are useful in treating a mammal that has experienced an ischemic event or that is at risk of experiencing such an event.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 22 OF 46 USPATFULL on STN  
AN 2002:98917 USPATFULL  
TI Drug delivery via therapeutic hydrogels  
IN DiCosmo, Frank, Richmond Hill, CANADA  
DiTizio, Valerio, North York, CANADA  
PI US 2002051812 A1 20020502  
AI US 2001-849481 A1 20010507 (9)  
RLI Division of Ser. No. US 1999-412584, filed on 5 Oct 1999, GRANTED, Pat. No. US 6228393 Continuation of Ser. No. US 1997-843342, filed on 15 Apr 1997, GRANTED, Pat. No. US 6132765 Continuation-in-part of Ser. No. US 1996-631326, filed on 12 Apr 1996, ABANDONED  
DT Utility  
FS APPLICATION  
LREP Brian P. O'Shaughnessy, BURNS, DOANE, SWECKER & MATHIS, L.L.P., P.O. Box 1404, Alexandria, VA, 22313-1404  
CLMN Number of Claims: 42  
ECL Exemplary Claim: 1  
DRWN 5 Drawing Page(s)  
LN.CNT 1018

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to a vehicle for effecting drug delivery from a solid substrate. Hydrogels loaded with liposomal therapeutic agents such as antibiotics are covalently bonded to the surface of substrates such as in-dwelling medical devices, such as implants, catheters, and the like. The present invention is particularly



09567863

useful in the treatment and prevention of biofilm mediated infection often associated with the use of in-dwelling medical devices.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 23 OF 46 USPATFULL on STN  
AN 2002:16609 USPATFULL  
TI Drug delivery via therapeutic hydrogels  
IN DiCosmo, Frank, Richmond Hill, CANADA  
DiTizio, Valerio, Toronto, CANADA  
PI US 2002009485 A1 20020124  
US 6475516 B2 20021105  
AI US 2001-818649 A1 20010328 (9)  
RLI Continuation of Ser. No. US 1999-412584, filed on 5 Oct 1999, GRANTED,  
Pat. No. US 6228393 Continuation of Ser. No. US 1997-843342, filed on 15  
Apr 1997, GRANTED, Pat. No. US 6132765 Continuation-in-part of Ser. No.  
US 1996-631326, filed on 12 Apr 1996, ABANDONED  
DT Utility  
FS APPLICATION  
LREP Lola A. Bartoszewicz, Sim & McBurney, 6th Floor, 330 University Avenue,  
Toronto, ON, M5G 1R7  
CLMN Number of Claims: 20  
ECL Exemplary Claim: 1  
DRWN 5 Drawing Page(s)  
LN.CNT 979

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to a vehicle for effecting drug delivery from a solid substrate. Hydrogels loaded with liposomal therapeutic agents such as antibiotics are covalently bonded to the surface of substrates such as in-dwelling medical devices, such as implants, catheters, and the like. The present invention is particularly useful in the treatment and prevention of biofilm mediated infection often associated with the use of in-dwelling medical devices.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 24 OF 46 USPATFULL on STN  
AN 2002:316990 USPATFULL  
TI Methods for enhancing fluid flow through an obstructed vascular site, and systems and kits for use in practicing the same  
IN Constantz, Brent R., Menlo Park, CA, United States  
Delaney, Dave, Menlo Park, CA, United States  
Hankermeyer, Christine, Menlo Park, CA, United States  
PA Corazon Technologies, Inc., Menlo Park, CA, United States (U.S. corporation)  
PI US 6488671 B1 20021203  
AI US 2000-528576 20000320 (9)  
RLI Continuation-in-part of Ser. No. US 1999-425826, filed on 22 Oct 1999, now patented, Pat. No. US 6290689  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Walberg, Teresa; Assistant Examiner: Dahbour, Fadi H.  
LREP Field, Bret E., Bozicevic, Field & Francis  
CLMN Number of Claims: 37  
ECL Exemplary Claim: 1  
DRWN 16 Drawing Figure(s); 12 Drawing Page(s)  
LN.CNT 1855  
AB Methods of enhancing fluid flow through a vascular site occupied by a vascular occlusion, as well as systems and kits for use in practicing the same, are provided. In practicing the subject methods, the vascular site is flushed simultaneously with a first dissolution fluid and a second dissolution fluid attenuating fluid, where flushing is carried

out in a manner such that only a surface of the vascular occlusion is contacted with the non-attenuated dissolution fluid. Flushing is carried out in this manner for a period of time sufficient for fluid flow through the vascular site to be enhanced, e.g. increased or established. The subject methods, systems and kits for practicing the same find use in the treatment of a variety of different vascular diseases characterized by the presence of vascular occlusions, including both partial and total occlusions.

L8 ANSWER 25 OF 46 USPATFULL on STN  
 AN 2002:194880 USPATFULL  
 TI Reverse micelles for delivery of nucleic acids  
 IN Monahan, Sean D., Madison, WI, United States  
 Wolff, Jon A., Madison, WI, United States  
 Slattum, Paul M., Madison, WI, United States  
 Hagstrom, James E., Madison, WI, United States  
 Budker, Vladimir G., Madison, WI, United States  
 PA Mirus Corporation, Madison, WI, United States (U.S. corporation)  
 PI US 6429200 B1 20020806  
 AI US 1999-354957 19990716 (9)  
 PRAI US 1998-93227P 19980717 (60)  
 DT Utility  
 FS GRANTED  
 EXNAM Primary Examiner: Guzo, David  
 LREP Johnson, Mark K.  
 CLMN Number of Claims: 17  
 ECL Exemplary Claim: 1  
 DRWN 1 Drawing Figure(s); 1 Drawing Page(s)  
 LN.CNT 1480  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB A complex is described for delivery to a cell comprising inserting a nucleic acid into a reverse micelle. The reverse micelle has the property to compact the nucleic acid for easier delivery. Other molecules are used to interact with the nucleic acid--micelle complex to further enhance delivery such as a surfactant having a disulfide bond.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 26 OF 46 USPATFULL on STN  
 AN 2002:194571 USPATFULL  
 TI Personal care articles  
 IN Cen, Raymond Wei, Cincinnati, OH, United States  
 Phipps, Nichola Jacqueline, Warfield, UNITED KINGDOM  
 Smith, III, Edward Dewey, Mason, OH, United States  
 PA The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)  
 PI US 6428799 B1 20020806  
 AI US 1999-442298 19991119 (9)  
 PRAI US 1999-146814P 19990802 (60)  
 DT Utility  
 FS GRANTED  
 EXNAM Primary Examiner: Page, Thurman K.; Assistant Examiner: Howard, S.  
 LREP Matthews, Armina E., Kendall, Dara M., Rosnell, Tara M.  
 CLMN Number of Claims: 20  
 ECL Exemplary Claim: 1  
 DRWN 0 Drawing Figure(s); 0 Drawing Page(s)  
 LN.CNT 4308  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB The present invention relates to a substantially dry, disposable personal care article suitable for cleansing and/or therapeutically treating comprising a water insoluble substrate which comprises a

non-scouring, lofty, low density batting layer which comprises synthetic fibers and wherein said batting layer exhibits a number of physical properties either individually or in combination which are believed to contribute to the overall effectiveness of the personal care article of the present invention. The physical properties of the batting include a Lather Permeability of at least 0.2 g/sec at 7 cm H.sub.20, a Lather Permeability Critical Pressure of less than about 4 cm H.sub.20, an Air Permeability of at least 900 ft.sup.3/min/ft.sup.2, a Compression Relaxation Hysteresis Value of from about 25% to about 60%, and an Abrasiveness Value of greater than about 15. These articles have been found to be particularly useful for personal cleansing applications, namely for the skin and hair.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 27 OF 46 USPTFULL on STN  
 AN 2002:39955 USPTFULL  
 TI Antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases  
 IN Squires, Meryl, Willowbrook, IL, United States  
 PA Squires, Meryl J., Barrington Hills, IL, United States (U.S. individual)  
 PI US 6350784 B1 20020226  
 AI US 1997-824041 19970326 (8)  
 RLI Continuation-in-part of Ser. No. US 1996-646988, filed on 8 May 1996  
 Continuation-in-part of Ser. No. US 1996-600217, filed on 12 Feb 1996  
 DT Utility  
 FS GRANTED  
 EXNAM Primary Examiner: Jones, Dwayne C.  
 LREP Welsh & Katz, Ltd., Tolpin, Thomas W.  
 CLMN Number of Claims: 2  
 ECL Exemplary Claim: 1  
 DRWN 0 Drawing Figure(s); 0 Drawing Page(s)  
 LN.CNT 2389

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An improved medical treatment and medicine is provided to quickly and safely resolve HIV and other microbial infections. The inexpensive medicine can be self administered and maintained for the prescribed time. The attractive medicine comprises an antimicrobial concentrate comprising microbe inhibitors, phytochemicals or isolates. Desirably, the effective medicine comprises a surfactant and an aqueous carrier or solvent and a nutrient. In the preferred form, the medicine comprises: Echinacea and Commiphora myrrha phytochemicals, benzalkonium chloride, a sterile water solution, and folic acid.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 28 OF 46 USPTFULL on STN  
 AN 2002:9654 USPTFULL  
 TI Cleansing articles for skin and/or hair which also deposit skin care actives  
 IN Albacarys, Lourdes Dessus, West Chester, OH, United States  
 McAtee, David Michael, Mason, OH, United States  
 Deckner, George Endel, Cincinnati, OH, United States  
 PA The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)  
 PI US 6338855 B1 20020115  
 AI US 1999-296334 19990422 (9)  
 RLI Continuation-in-part of Ser. No. US 1998-65991, filed on 24 Apr 1998, now abandoned Continuation-in-part of Ser. No. US 1997-974033, filed on 19 Nov 1997, now abandoned Continuation-in-part of Ser. No. US 1996-738145, filed on 25 Oct 1996, now abandoned Continuation of Ser. No. US 1996-738668, filed on 25 Oct 1996, now abandoned

09567863

PRAI US 1998-83015P 19980424 (60)  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Criares, Theodore J.  
LREP Allen, George W., Matthews, Armina E., Tsuneki, Fumiko  
CLMN Number of Claims: 29  
ECL Exemplary Claim: 1  
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)  
LN.CNT 3405

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a substantially dry, disposable, personal cleansing article useful for both cleansing the skin or hair and delivering skin care actives onto the skin or hair. These articles are used by the consumer by (i) wetting the dry article with water and (ii) generating lather by subjecting the wetted article to mechanical forces, e.g., rubbing. The article comprises a water insoluble substrate, a lathering surfactant, and a skin care active component. Preferably, the articles of the present invention further comprise a deposition aid and/or a conditioning component.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 29 OF 46 USPATFULL on STN  
AN 2001:211923 USPATFULL  
TI Method for administering a cytokine to the central nervous system and the lymphatic system  
IN Frey, William H., II, North Oaks, MN, United States  
PA Chiron Corporation (U.S. corporation)  
PI US 2001043915 A1 20011122  
AI US 2000-733168 A1 20001208 (9)  
PRAI US 1999-200708P 19991209 (60)  
DT Utility  
FS APPLICATION  
LREP Joseph H. Guth, Esq., Corporate Patent Counsel, CHIRON CORPORATION, P.O. Box 8097, Emeryville, CA, 94662-8097  
CLMN Number of Claims: 60  
ECL Exemplary Claim: 1  
DRWN 1 Drawing Page(s)  
LN.CNT 2997

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to a method for delivering cytokines to the central nervous system and the lymphatic system by way of a **tissue** innervated by the trigeminal nerve and/or olfactory nerve. Cytokines include tumor necrosis factors, interleukins, interferons, particularly interferon- $\beta$  and its muteins such as IFN- $\beta$ .sub.ser17. Such a method of delivery can be useful in the treatment of central nervous system disorders, brain disorders, proliferative, viral, and/or autoimmune disorders such as Sjogren's disorder.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 30 OF 46 USPATFULL on STN  
AN 2001:200303 USPATFULL  
TI Methods for enhancing fluid flow through an obstructed vascular site, and systems and kits for use in practicing the same  
IN Johansson, Peter, Campbell, CA, United States  
Delaney, David, Los Gatos, CA, United States  
Constantz, Brent, Menlo Park, CA, United States  
PI US 2001039411 A1 20011108  
US 6533767 B2 20030318  
AI US 2001-774469 A1 20010130 (9)

09567863

RLI Continuation-in-part of Ser. No. US 2000-528576, filed on 20 Mar 2000,  
UNKNOWN  
DT Utility  
FS APPLICATION  
LREP Bret E. Field, BOZICEVIC, FIELD & FRANCIS LLP, 200 Middlefield Road,  
Suite 200, Menlo Park, CA, 94025  
CLMN Number of Claims: 51  
ECL Exemplary Claim: 1  
DRWN 10 Drawing Page(s)  
LN.CNT 2216  
AB Methods of enhancing fluid flow through a vascular site occupied by a  
vascular occlusion, as well as systems and kits for use in practicing  
the same, are provided. In practicing the subject methods, the vascular  
site is flushed simultaneously with a first dissolution fluid (e.g., an  
organic matter dissolution fluid and/or an inorganic matter dissolution  
fluid), and a second dissolution fluid attenuating fluid, where flushing  
is carried out in a manner such that only a surface of the vascular  
occlusion is contacted with the non-attenuated dissolution fluid.  
Examples of dissolution fluid/dissolution fluid attenuating fluid pairs  
include: (1) oxidizing agent fluid and fluid comprising oxidizable  
neutralizing agent; (2) surfactant fluid and phosphate buffered saline;  
(3) acidic solution and phosphate buffered saline; etc. Flushing is  
carried out in this manner for a period of time sufficient for fluid  
flow through the vascular site to be enhanced, e.g. increased or  
established. The subject methods, systems and kits for practicing the  
same find use in the treatment of a variety of different vascular  
diseases characterized by the presence of vascular occlusions, including  
both partial and total occlusions.

L8 ANSWER 31 OF 46 USPATFULL on STN  
AN 2001:234992 USPATFULL  
TI Nanogel networks and biological agent compositions thereof  
IN Kabanov, Alexander V., Omaha, NE, United States  
Vinogradov, Sergey V., Omaha, NE, United States  
PA Supratek Pharma, Inc., Canada (non-U.S. corporation)  
PI US 6333051 B1 20011225  
AI US 1998-146651 19980903 (9)  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Riley, Jezia  
LREP Mathews, Collins, Shepherd & Gould, P.A.  
CLMN Number of Claims: 12  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 2246

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Copolymer networks having at least one cross-linked polyamine polymer  
fragment and at least one nonionic water-soluble polymer fragment, and  
compositions thereof, having at least one suitable biological agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 32 OF 46 USPATFULL on STN  
AN 2001:121065 USPATFULL  
TI Attaching agents to **tissue** with transglutaminase and a  
transglutaminase substrate  
IN Green, Howard, 82 Williston St., Brookline, MA, United States 02146  
Corey, George D., 65 Harding St., Newton, MA, United States 02165  
Compton, Bruce J., 30 Cottage St., Lexington, MA, United States 02173  
Dijan, Philippe, 170, rue de la Convention, 75015 Paris, France  
PI US 6267957 B1 20010731

09567863

AI US 1999-234358 19990120 (9)  
PRAI US 1998-71908P 19980120 (60)  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Naff, David M.  
LREP Wolf, Greenfield & Sacks, P.C.  
CLMN Number of Claims: 48  
ECL Exemplary Claim: 1  
DRWN 3 Drawing Figure(s); 2 Drawing Page(s)  
LN.CNT 1730

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods, products and kits are provided for attaching agents to **tissue** with a linking molecule in the presence of transglutaminase. The linking molecule and/or agent is a substrate of transglutaminase. The agent can be a nonprotein or an enzyme such as cholinesterase or phosphodiesterase. The transglutaminase may be exogenously added or be endogenous in **tissue**. In specific embodiments, the linking molecule contains at least two contiguous linked glutamines or at least three contiguous linked lysines. A conjugate of the agent and the linking molecule may be applied to **tissue**, and in the presence of transglutaminase covalently bonded to the **tissue** via the linking molecule. A complementary linking molecule rich in lysines may be first attached to the **tissue** in the presence of transglutaminase, and then covalently bonded to a glutamine-containing linking molecule of the conjugate in the presence of transglutaminase. In another embodiment, a linking molecule containing multiple glutamines is covalently bonded to **tissue** in the presence of transglutaminase, and an agent containing multiple lysines is covalently bonded to the linking molecule in the presence of transglutaminase. Alternatively, the linking molecule contains multiple lysines and the agent contains multiple glutamines. Two tissues can be sealed together by holding the tissues in contact with each other in the presence of transglutaminase.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 33 OF 46 USPATFULL on STN  
AN 2001:93312 USPATFULL  
TI Assay of denatured lipoproteins  
IN Kondo, Akira, Tokyo, Japan  
Toda, Naoko, Tokyo, Japan  
Kobayashi, Noriko, Tokyo, Japan  
Nozawa, Masayuki, Tokyo, Japan  
Manabe, Mitsuhsa, Tokyo, Japan  
PA Daiichi Pure Chemicals Co., Ltd., Tokyo, Japan (non-U.S. corporation)  
PI US 6248545 B1 20010619  
AI US 1997-949911 19971014 (8)  
RLI Continuation of Ser. No. US 1994-327105, filed on 21 Oct 1994, now abandoned  
PRAI JP 1993-264809 19931022  
JP 1994-181329 19940802  
JP 1994-190279 19940812  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Duffy, Patricia A.  
LREP Bacon & Thomas  
CLMN Number of Claims: 26  
ECL Exemplary Claim: 1  
DRWN 11 Drawing Figure(s); 11 Drawing Page(s)  
LN.CNT 854

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed herein is an assay of a denatured lipoprotein, in which the

09567863

denatured site of the denatured lipoprotein contained in a vital sample is exposed to the surface of its lipoprotein particle upon the reaction of an antibody, which recognizes the denatured lipoprotein, with the vital sample containing the denatured lipoprotein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 34 OF 46 USPATFULL on STN  
AN 2001:67204 USPATFULL  
TI Drug delivery via therapeutic hydrogels  
IN DiCosmo, Frank, Richmond Hill, Canada  
DiTizio, Valerio, North York, Canada  
PA Uroteq, Inc., Canada (non-U.S. corporation)  
PI US 6228393 B1 20010508  
AI US 1999-412584 19991005 (9)  
RLI Continuation of Ser. No. US 1997-843342, filed on 15 Apr 1997, now patented, Pat. No. US 6132765 Continuation-in-part of Ser. No. US 1996-631326, filed on 12 Apr 1996, now abandoned  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Kishore, Gollamudi S.  
LREP Burns, Doane, Swecker & Mathis, L.L.P.  
CLMN Number of Claims: 25  
ECL Exemplary Claim: 1  
DRWN 7 Drawing Figure(s); 5 Drawing Page(s)  
LN.CNT 1106

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to a vehicle for effecting drug delivery from a solid substrate. Hydrogels loaded with liposomal therapeutic agents such as antibiotics are covalently bonded to the surface of substrates such as in-dwelling medical devices, such as implants, catheters, and the like. The present invention is particularly useful in the treatment and prevention of biofilm mediated infection often associated with the use of in-dwelling medical devices.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 35 OF 46 USPATFULL on STN  
AN 2000:174129 USPATFULL  
TI Preparation for the application of agents in mini-droplets  
IN Cevc, Gregor, Heimstetten, Germany, Federal Republic of  
PA Idea AG, Munich, Germany, Federal Republic of (non-U.S. corporation)  
PI US 6165500 20001226  
AI US 1992-844664 19920408 (7)  
PRAI DE 1990-4026834 19900824  
DE 1990-4026833 19900824  
DE 1991-4107153 19910306  
WO 1991-EP1596 19910822  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Kishore, Gollamudi S.  
LREP Davidson, Davidson & Kappel, LLC  
CLMN Number of Claims: 35  
ECL Exemplary Claim: 1  
DRWN 31 Drawing Figure(s); 21 Drawing Page(s)  
LN.CNT 4336

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a preparation for the application of agents in the form of minuscule droplets of fluid, in particular provided with membrane-like structures consisting of one or several layers of amphiphilic molecules, or an amphiphilic carrier substance, in particular for transporting the agent into and through natural barriers

09567863

such as skin and similar materials. The preparation contains a concentration of edge active substances which amounts to up to 99 mol-% of the agent concentration which is required for the induction of droplet solubilization. Such preparations are suitable, for example, for the non-invasive applications of antidiabetics, in particular of insulin. The invention, moreover, relates to the methods for the preparation of such formulations.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 36 OF 46 USPATFULL on STN  
AN 2000:137855 USPATFULL  
TI Drug delivery via therapeutic hydrogels  
IN DiCosmo, Frank, Richmond Hill, Canada  
DiTizio, Valerio, North York, Canada  
PA Uroteq Inc., Ontario, Canada (non-U.S. corporation)  
PI US 6132765 20001017  
AI US 1997-843342 19970415 (8)  
RLI Continuation-in-part of Ser. No. US 1996-631326, filed on 12 Apr 1996, now abandoned  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Kishore, Gollamudi S.  
LREP Burns, Doane, Swecker & Mathis, L.L.P.  
CLMN Number of Claims: 18  
ECL Exemplary Claim: 1  
DRWN 5 Drawing Figure(s); 5 Drawing Page(s)  
LN.CNT 1097

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to a vehicle for effecting drug delivery from a solid substrate. Hydrogels loaded with liposomal therapeutic agents such as antibiotics are covalently bonded to the surface of substrates such as in-dwelling medical devices, such as implants, catheters, and the like. The present invention is particularly useful in the treatment and prevention of biofilm mediated infection often associated with the use of in-dwelling medical devices.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 37 OF 46 USPATFULL on STN  
AN 2000:87749 USPATFULL  
TI Oral peptide pharmaceutical products  
IN Stern, William, Tenafly, NJ, United States  
Gilligan, James P., Union, NJ, United States  
PA Unigene Laboratories, Inc., Fairfield, NJ, United States (U.S. corporation)  
PI US 6086918 20000711  
WO 9733531 19970918  
AI US 1998-125500 19980819 (9)  
WO 1997-US4024 19970314  
19980819 PCT 371 date  
19980819 PCT 102(e) date  
RLI Continuation-in-part of Ser. No. US 1996-616250, filed on 15 Mar 1996, now patented, Pat. No. US 5912014  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Salimi, Ali  
LREP Ostrolenk, Faber, Gerb & Soffen, LLP  
CLMN Number of Claims: 55  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1353



09567863

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Bioavailability of peptide active agents to be administered orally is enhanced by a pharmaceutical composition providing targeted release of the peptide to the intestine by virtue of an acid-resistant protective vehicle which transports components of the invention through the stomach. The composition includes an absorption enhancer and a sufficient amount of a pH-lowering agent to lower local intestinal pH. All components are released together into the intestine with the peptide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 38 OF 46 USPATFULL on STN  
AN 1999:75769 USPATFULL  
TI Isolation of lactoferrin from milk  
IN Nuyens, Jan H., MV Ileiloo, Netherlands  
Van Veen, Harry H., NB Boskoop, Netherlands  
PA Pharming B.V., Leiden, Netherlands (non-U.S. corporation)  
PI US 5919913 19990706  
AI US 1995-406271 19950309 (8)  
RLI Continuation of Ser. No. US 1994-198321, filed on 16 Feb 1994, now abandoned  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Degen, Nancy  
LREP Townsend & Townsend & Crew  
CLMN Number of Claims: 27  
ECL Exemplary Claim: 1  
DRWN 13 Drawing Figure(s); 13 Drawing Page(s)  
LN.CNT 1883

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides methods for purification of human lactoferrin from milk, especially milk of nonhuman species, and for separation of human lactoferrin from undesired macromolecular species present in the milk, including separation from nonhuman lactoferrin species.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 39 OF 46 USPATFULL on STN  
AN 1999:7477 USPATFULL  
TI Isolation of lactoferrin from milk  
IN Nuijens, Jan H, Heiloo, Netherlands  
Van Veen, Harry H, Boskoop, Netherlands  
PA Pharming B.V., Leiden, Netherlands (non-U.S. corporation)  
PI US 5861491 19990119  
WO 9522258 19950824  
AI US 1996-693274 19961016 (8)  
WO 1995-EP583 19950216  
19961016 PCT 371 date  
19961016 PCT 102(e) date

DT Utility  
FS Granted  
EXNAM Primary Examiner: Degen, Nancy  
LREP Townsend & Townsend & Crew LLP  
CLMN Number of Claims: 11  
ECL Exemplary Claim: 1  
DRWN 15 Drawing Figure(s); 15 Drawing Page(s)  
LN.CNT 1821

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides methods for purification of human lactoferrin from milk, especially milk of nonhuman species, and for separation of human lactoferrin from undesired macromolecular species present in the

09567863

milk, including separation from nonhuman lactoferrin species.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 40 OF 46 USPATFULL on STN  
AN 1998:157484 USPATFULL  
TI Isolation of lactoferrin from milk  
IN Nuyens, Jan H., Heiloo, Netherlands  
Van Veen, Harry H., Boskoop, Netherlands  
PA Gene Pharming Europe B.V., Leiden, Netherlands (non-U.S. corporation)  
PI US 5849885 19981215  
AI US 1995-464182 19950605 (8)  
RLI Continuation of Ser. No. US 1995-406271, filed on 9 Mar 1995 which is a continuation of Ser. No. US 1994-198321, filed on 16 Feb 1994, now abandoned  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Degen, Nancy  
LREP Townsend and Townsend and Crew LLP  
CLMN Number of Claims: 27  
ECL Exemplary Claim: 1  
DRWN 13 Drawing Figure(s); 13 Drawing Page(s)  
LN.CNT 1818

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides methods for purification of human lactoferrin from milk, especially milk of nonhuman species, and for separation of human lactoferrin from undesired macromolecular species present in the milk, including separation from nonhuman lactoferrin species.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 41 OF 46 USPATFULL on STN  
AN 1998:51806 USPATFULL  
TI Hydroxy containing alkyl glycamides, low foaming detergent compositions comprising such and a process for their manufacture  
IN Vermeer, Robert, Nutley, NJ, United States  
Harichian, Bijan, South Orange, NJ, United States  
PA Lever Brothers Company, Division of Conopco, Inc., New York, NY, United States (U.S. corporation)  
PI US 5750733 19980512  
AI US 1996-689178 19960806 (8)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Ngo, Tamthom T.  
LREP Koatz, Ronald A.  
CLMN Number of Claims: 9  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 3217

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel hydroxy-containing alkyl glycamide surfactants and detergent composition comprising said surfactants. Since they surprisingly provide low foam, these surfactants can be used as cleansing surfactants in applications where low foaming is desirable.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 42 OF 46 USPATFULL on STN  
AN 96:45927 USPATFULL  
TI Bone marrow cell adhesion molecules and process for detecting adherence between cell adhesion molecules and cells generally

09567863

IN Seshi, Beerelli, Fairport, NY, United States  
PA University of Rochester, Rochester, NY, United States (U.S. corporation)  
PI US 5521067 19960528  
AI US 1993-158936 19931124 (8)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Saunders, David  
LREP Nixon, Hargrave, Devans & Doyle  
CLMN Number of Claims: 8  
ECL Exemplary Claim: 1  
DRWN 40 Drawing Figure(s); 11 Drawing Page(s)  
LN.CNT 2197

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to proteins associated with human bone marrow cell membranes for adhering hematopoietic cells to human bone marrow cell membranes. These proteins are soluble in lithium dodecyl sulfate but insoluble in 2% nonaethylene glycol octylphenol ether (e.g., 2% Triton® X-100) solution. These proteins and antibodies raised against them are useful in the treatment and diagnosis of blood disorders. The DNA molecules encoding these proteins have use in gene therapy regimes. Also disclosed is a method for detecting binding between cell adhesion membrane proteins and cells having a potential to be bound to such proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 43 OF 46 USPATFULL on STN  
AN 95:24830 USPATFULL  
TI Use of blocking protein with high pH extraction in method to determine a microorganism associated with periodontal disease and kit useful therefor  
IN Boyer, Bradley P., Rochester, NY, United States  
Contestable, Paul B., Rochester, NY, United States  
Snyder, Brian A., Rochester, NY, United States  
PA Eastman Kodak Company, Rochester, NY, United States (U.S. corporation)  
PI US 5399484 19950321  
AI US 1991-773064 19911008 (7)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Bidwell, Carol E.  
LREP Tucker, James L.  
CLMN Number of Claims: 18  
ECL Exemplary Claim: 9  
DRWN No Drawings  
LN.CNT 1132

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method has been developed for determining microorganisms associated with periodontal diseases which is highly sensitive and shows very low background and cross-reactivity among various closely related antigens. Antigen is extracted at relatively high pH, and either before or immediately after extraction, the antigen-containing specimen is mixed with a blocking composition having at least about 0.2 weight percent of a non-immunoreactive blocking protein. The pH of the resulting mixture is kept high when contacted with the antibodies specific to the antigen of interest. The compositions and components needed for the assay can be supplied in a diagnostic test kit.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


L8 ANSWER 44 OF 46 USPATFULL on STN  
AN 95:1532 USPATFULL  
TI Wash composition for determination of microorganisms associated with

09567863

periodontal diseases  
IN Boyer, Bradley P., Rochester, NY, United States  
Contestable, Paul B., Rochester, NY, United States  
Snyder, Brian A., Rochester, NY, United States  
PA Eastman Kodak Company, Rochester, NY, United States (U.S. corporation)  
PI US 5378629 19950103  
AI US 1993-72029 19930607 (8)  
RLI Division of Ser. No. US 1991-774019, filed on 8 Oct 1991, now patented,  
Pat. No. US 5248595  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Housel, James C.; Assistant Examiner: Le, Long V.  
LREP Tucker, J. Lanny  
CLMN Number of Claims: 8  
ECL Exemplary Claim: 1  
DRWN 6 Drawing Figure(s); 5 Drawing Page(s)  
LN.CNT 1171

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An aqueous wash composition has been found useful in methods for determination of specific binding ligands. The composition is buffered to a pH of less than or equal to 6 or greater than or equal to 9. It also includes as its essential component at least about 0.1 weight percent of an anionic surfactant which is represented by the formula:



wherein A is a hydrocarbon having a molecular weight of at least about 180, X<sup>+m</sup> is hydrogen or a monovalent or divalent cation, m is 1 or 2, is 0 or 1, and n is 1 or 2 provided that m and n are not both 2. Optionally and preferably, the wash composition also includes a nonimmunoreactive protein. This wash composition is particularly useful in methods for determination of microorganisms associated with periodontal diseases. Such methods can be of a variety of formats, but immunometric assays are particularly useful. The wash composition can be included as part of a diagnostic test kit.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 45 OF 46 USPATFULL on STN  
AN 93:80669 USPATFULL  
TI Wash composition, test kit and method for determination of microorganisms associated with periodontal diseases  
IN Boyer, Bradley P., Rochester, NY, United States  
Contestable, Paul B., Rochester, NY, United States  
Snyder, Brian A., Rochester, NY, United States  
PA Eastman Kodak Company, Rochester, NY, United States (U.S. corporation)  
PI US 5248595 19930928  
AI US 1991-774019 19911008 (7)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Kepplinger, Esther L.; Assistant Examiner: Green, Lora Marie  
LREP Tucker, J. Lanny  
CLMN Number of Claims: 13  
ECL Exemplary Claim: 1  
DRWN 6 Drawing Figure(s); 5 Drawing Page(s)  
LN.CNT 1190

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An aqueous wash composition has been found useful in methods for determination of specific binding ligands. The composition is buffered to a pH of less than or equal to 6 or greater than or equal to 9. It also includes as its essential component at least about 0.1 weight

percent of an anionic surfactant which is represented by the formula:



wherein A is a hydrocarbon having a molecular weight of at least about 180,  $X^{+m}$  is hydrogen or a monovalent or divalent cation, m is 1 or 2, y is 0 or 1, and n is 1 or 2 provided that m and n are not both 2. Optionally and preferably, the wash composition also includes a nonimmunoreactive protein. This wash composition is particularly useful in methods for determination of microorganisms associated with periodontal diseases. Such methods can be of a variety of formats, but immunometric assays are particularly useful. The wash composition can be included as part of a diagnostic test kit.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 46 OF 46 USPATFULL on STN  
 AN 93:61013 USPATFULL  
 TI Use of heme-containing proteins as stabilizers for enzyme-labeled immunoreactants  
 IN Warren, III, Harold C., Rush, NY, United States  
 Boyer, Bradley P., Rochester, NY, United States  
 PA Eastman Kodak Company, Rochester, NY, United States (U.S. corporation)  
 PI US 5231004 19930727  
 AI US 1990-522441 19900511 (7)  
 DT Utility  
 FS Granted  
 EXNAM Primary Examiner: Kepplinger, Esther L.; Assistant Examiner: Bidwell, Carol E.  
 LREP Tucker, J. Lanny  
 CLMN Number of Claims: 15  
 ECL Exemplary Claim: 10  
 DRWN 1 Drawing Figure(s); 1 Drawing Page(s)  
 LN.CNT 1098

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Heme-containing proteins, such as cytochrome c, are useful in admixture with enzyme-labeled immunoreactants, such as peroxidase-labeled antibodies or fragments thereof. The heme-containing proteins and enzyme-labeled immunoreactants can be supplied in a buffered composition as part of a test kit. The buffered composition comprising the heme-containing protein and peroxidase-labeled immunoreactant excludes 4'-hydroxyacetanilide, which is a phenolic electron transfer agent. The composition can be used in immunoassays for detecting various immunologically reactive species, such as hCG, and chlamydial or gonococcal antigens.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.